Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
Side-by-side research view
Compare names across metrics and research quality
Use up to 4 U.S.-listed names from this dashboard to compare valuation, growth, cash flow, balance-sheet strength, and the curated investment case in one place.
1 stocks in current compare
4 max names side by side
24 shared metrics lined up
Build a compare set
Enter comma-separated tickers from the dashboard universe. Duplicate tickers are ignored automatically.
Price
$287.50
1D change
-2.29%
Market cap
$110.11B
Sector
Healthcare
| Metric | SYK |
|---|---|
| Price | $287.50 |
| 1D Change | -2.29% |
| Market Cap | $110.11B |
| Enterprise Value | $123.92B |
| Trailing P/E | 33.2 |
| Forward P/E | 17.2 |
| Price / Sales | 4.4 |
| EV / Revenue | 4.9 |
| Revenue Growth | 2.6% |
| Earnings Growth | 14.2% |
| Gross Margin | 64.7% |
| Operating Margin | 17.8% |
| Net Margin | 13.2% |
| ROE | 15.2% |
| Free Cash Flow | $4.89B |
| FCF Margin | 19.3% |
| Debt / Equity | 0.62x |
| Current Ratio | 2.11x |
| Dividend Yield | 120.00% |
| Next Earnings | Jul 30, 2026 |
| Quarterly Revenue | $7.17B |
| Revenue QoQ | +18.4% |
| Quarterly Net Income | $849.0M |
| Net Income QoQ | -1.2% |
SYK thesis lens
Orthopedic robotics platform
Why it could benefit
- Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
- Recent expansion into handheld robotics broadens the Mako platform and gives the sleeve another real medical-robotics leader.
- It adds exposure to hospital robotics without relying on the exact same thesis as Intuitive.
Moat / edge
- Established Mako installed base and surgeon workflow integration.
- Strong orthopedic distribution and clinical relationships.
- A robotics platform that can expand across procedures over time.
What to watch
- Mako placements and utilization.
- Adoption of new handheld robotics offerings.
- How much robotics continues to differentiate Stryker in orthopedics.
Key risks
- Hospital budgets and elective procedure trends can affect demand.
- The robotics narrative is important, but it still sits inside a broader medtech company.